Basal-Prandial-Correctional Insulin Regimen in Managing High Blood Sugar in Hospitalized Cancer Patients

Inclusion Criteria

• Provision of signed and dated informed consent form.
• Stated willingness to comply with all study procedures and availability for the duration of the study.
• Provide race and ethnicity information.
• Diagnosed with cancer.
• Hospitalized at H. Lee Moffitt Cancer Center and Research Institute (MCC) in the medical, hematologic, or bone marrow transplant units.
• Having in-hospital hyperglycemia with or without a pre-existing diagnosis of diabetes mellitus (DM), with 2 measurements of BG > 180 mg/dL and/or 1 measurement of BG > 350 mg/dL within the first 72 hours of hospitalization, detected by bedside point-of-care testing and/or basic metabolic panel laboratory data.
• Patients enrolled in other clinical trials are admissible to this trial.

Exclusion Criteria

• Patients at the end of life and/or with limited life expectancies (< 6 months).
• Patients of non-Hispanic descent
• Patients without cancer diagnoses.
• Surgical patients and patients admitted directly to the intensive care unit, other than those in the Bone Marrow Transplant Unit, who are included.
• Patients treated and discharged in outpatient settings (i.e., direct referral center, infusion center, or clinical research unit) or those admitted for observation only (hospitalized less than 24 hours).
• Patients on total parenteral nutrition.
• Patients on insulin pumps.
• Patients admitted with diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome.
• Pregnant patients based on medical history.
• Patients being followed by Moffitt Cancer Center endocrinology department for management of hyperglycemia or hypoglycemia